Key Highlights
• The global market for the nephrology pharmaceuticals is projected to witness exceptional growth during the forecast period due to the increased prevalence of kidney illness among millennials worldwide. The treatment of ailments including chronic kidney diseases and acute renal illness by nephrology pharmaceuticals considerably contributes to the market's growth.
• The market for Nephrology Drugs was valued at USD 16.72 billion in 2022, and by 2032, it is anticipated to have grown to USD 28.35 billion, with a 6.12% CAGR from 2023 – 2032.
• In July 2022, Health Canada approved GlaxoSmithKline's (GSK) New Drug Submission (NDS) of daprodustat, an inhaled HIF-PHI that may be used to treat patients with anaemia associated with chronic kidney disease (CKD).
• Since lifestyle changes are causing millennials all over the world to suffer renal ailments such as fibrosis of the kidneys & kidney failure, the market is expected to grow dramatically over the next years. Due to the continual introduction of new medications and the ongoing development of existing nephrology drug products, the market is predicted to experience significant growth potential throughout the anticipated period. As attempts to create medications to treat chronic renal disease improve, the market is projected to expand. The increasing incidence of chronic nephrology ailments the number of elderly people, the increasing need for diagnostic tests, the consumption of excessive amounts of alcohol, the rise in cases of kidney failure, and a rise in the percentage of obese people are all factors that are contributing to the rise in demand for nephrology drugs.
Scope of the Industry Profile
Key Players
• AstraZeneca
• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Amgen Inc.
• F. Hoffmann-La Roche
• FibroGen Inc.
• Johnson & Johnson Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Limited
• Reata Pharmaceuticals, Inc.
• GlaxoSmithKline plc.
• Ardelyx, Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Novartis AG
Segmentation
By Drug Class
• ACE Inhibitors
• Angiotensin Receptor Blockers (ARBs)
• B-Blockers
• Calcium Channel Blockers
• Loop Diuretics
• Erythropoiesis-Stimulating Agents (ESAs)
• Phosphate Binders
• Others
By Route of Administration
• Oral
• Subcutaneous
• Intravenous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
What To Expect from Industry Profile
1. Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the Nephrology Drugs market in the world.
2. Use the PORTER’s Five Forces analysis to determine the competitive intensity and therefore market attractiveness of the Global Nephrology Drugs market.
3. Leading company profiles reveal details of key Nephrology Drugs market players’ global operations, strategies, financial performance & their recent developments.
4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Nephrology Drugs market with forecast for decade by both market share (%) & revenue (USD Million).
Recent Developments
• Aug’22 - In order to treat type-2 diabetes and chronic kidney disease (CKD), Bayer introduced finerenone in India.
• July'22 - Grupo Olmos, a company that provides renal care solutions, announced that it had acquired the renal care unit of Diaverum, an Argentinean renal healthcare provider. The acquisition of the kidney business will bolster the company's line of renal products.
• April’21 - Individuals suffering from chronic kidney disease who have a risk for disease progression, the USFDA has permitted Farxiga (dapagliflozin) in tablets form to lower the risk of renal function loss, kidney failure, cardiovascular mortality, and hospitalisation for heart failure.
Segment Insights
• Due to the increase in the incidence of multiple cardiovascular & hypertension problems as well as changing lifestyles, the ACE inhibitors category now dominates the global market for nephrology pharmaceuticals. Throughout the estimated duration, it is anticipated that this pattern will continue to exist.
• The oral segment led the global market for nephrology medications in 2022 when it came to route of administration. This is attributable to key players concentrating on the launch of innovative medications.
• The retail pharmacy category predominated the global market for nephrology pharmaceuticals in 2022 according to distribution channel, which is expected due to advancements in medical facilities and an increase in public healthcare spending.
z
Regional Insights
• North America is predicted to account for a sizeable portion of the worldwide market of chronic renal diseases during the span of the forecast year. The primary factors driving market expansion include increasing prevalence of chronic renal illness, an established healthcare system, high healthcare spending, and technologically advanced diagnostic techniques. The primary driver fuelling the market's expansion is the rising prevalence of chronic renal disorders in the population.
• The rising incidence of diabetes & coronary heart disease, new healthcare infrastructure alongside regulations, population expansion and growth, per capita income, expenditures on healthcare, as well as greater government efforts and public awareness, are among the key variables in the Asia-Pacific region.
1 INTRODUCTION
1.1 Study Objectives
1.2 Market Definitions
1.2.1 Inclusions & Exclusions
1.2.2 Region: Inclusions & Exclusions
1.2.3 Study Scope
1.2.3.1 Markets Covered
1.2.3.2 Regional Scope
1.2.3.3 Years Considered
1.2.4 Currency Considered
1.2.5 Limitations
1.2.6 Summary Of Report (Chapter Wise Summary)
2 RESEARCH
METHODOLOGY
2.1 Research Data
2.1.1 Secondary & Primary Research
2.1.2 Secondary Data
2.1.2.1 Secondary Sources
2.1.3 Primary Data
2.1.3.1 Primary Sources
2.2 Market Breakdown & Data
Triangulation
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Research Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 EXECUTIVE
SUMMARY
4 ACROSS
THE GLOBE
4.1 Upcoming Attractive Market
Opportunities
4.2 Country Wise Market Growth
4.3 Segment Wise Market Growth
5 MARKET
OVERVIEW
5.1 Market Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
5.3 PORTOR’S Five Forces Analysis
5.3.1 Threat of New Entrants
5.3.2 Threat of Substitutes
5.3.3 Bargaining Power of Suppliers
5.3.4 Bargaining Power of Buyers
5.3.5 Intensity of Competitive Rivalry
5.4 Market Premium insights (Enterprise
license)
5.4.1 Case Study Analysis
5.4.2 Country Wise Import & Export Data (If
Applicable)
5.4.3 Regulatory Bodies & Authorization
Across the Globe
5.4.4 Key Conferences & Events: 2022 &
2023
5.4.5 Top Patents for The Market: 2022
6 NEPHROLOGY
DRUGS MARKET OVERVIEW, BY ROUTE OF ADMINISTRATION
6.1 Global Market Revenue & Share
Analysis, By Route of Administration
6.1.1 Oral
6.1.2 Subcutaneous
6.1.3 Intravenous
6.2 Global Market Revenue & Share
Analysis, 2018 – 2022
6.3 Global Market Revenue & Share
Forecast Analysis, 2023 – 2032
6.4 Key Takeaways
7 NEPHROLOGY
DRUGS MARKET OVERVIEW, BY DISTRIBUTION CHANNEL
7.1 Global Market Revenue & Share
Analysis, By Distribution Channel
7.1.1 Hospital Pharmacies
7.1.2 Retail Pharmacies
7.1.3 Online Pharmacies
7.2 Global Market Revenue & Share
Analysis, 2018 – 2022
7.3 Global Market Revenue & Share
Forecast Analysis, 2023 – 2032
7.4 Key Takeaways
8 NEPHROLOGY
DRUGS MARKET OVERVIEW, BY DRUG CLASS
8.1 Global Market Revenue & Share
Analysis, By Drug Class
8.1.1 ACE Inhibitors
8.1.2 Angiotensin Receptor Blockers (ARBs)
8.1.3 B-Blockers
8.1.4 Calcium Channel Blockers
8.1.5 Loop Diuretics
8.1.6 Erythropoiesis-Stimulating Agents (ESAs)
8.1.7 Phosphate Binders
8.1.8 Others
8.2 Global Market Revenue & Share
Analysis, 2018 – 2022
8.3 Global Market Revenue & Share
Forecast Analysis, 2023 – 2032
8.4 Key Takeaways
9 NEPHROLOGY
DRUGS MARKET OVERVIEW, BY REGION
9.1 Global Market Revenue & Share
Analysis, By Region
9.1.1 North America
9.1.2 Europe
9.1.3 Asia Pacific
9.1.4 Middle East & Africa
9.1.5 South America
9.2 Global Market Revenue & Share
Analysis, 2018 – 2022
9.3 Global Market Revenue & Share Forecast
Analysis, 2023 – 2032
9.4 Key Takeaways
10 NORTH
AMERICA MARKET ANALYSIS
10.1 North America Market Revenue & Share
Analysis, By Route of Administration
10.2 North America Market Revenue & Share
Analysis, By Distribution Channel
10.3 North America Market Revenue & Share
Analysis, By Drug Class
10.4 North America Market Revenue & Share
Analysis, By Country
10.4.1 US
10.4.2 Canada
10.4.3 Mexico
10.5 Key Takeaways
11 EUROPE
MARKET ANALYSIS
11.1 Europe Market Revenue & Share
Analysis, By Route of Administration
11.2 Europe Market Revenue & Share
Analysis, By Distribution Channel
11.3 Europe Market Revenue & Share
Analysis, By Drug Class
11.4 Europe Market Revenue & Share
Analysis, By Country
11.4.1 UK
11.4.2 Italy
11.4.3 Spain
11.4.4 Germany
11.4.5 France
11.4.6 Rest of Europe
11.5 Key Takeaways
12 ASIA
PACIFIC MARKET ANALYSIS
12.1 APAC Market Revenue & Share Analysis,
By Route of Administration
12.2 APAC Market Revenue & Share Analysis,
By Distribution Channel
12.3 APAC Market Revenue & Share Analysis,
By Drug Class
12.4 APAC Market Revenue & Share Analysis,
By Country
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Rest of APAC
12.5 Key Takeaways
13 MIDDLE
EAST & AFRICA MARKET ANALYSIS
13.1 MEA Market Revenue & Share Analysis,
By Route of Administration
13.2 MEA Market Revenue & Share Analysis,
By Distribution Channel
13.3 MEA Market Revenue & Share Analysis,
By Drug Class
13.4 MEA Market Revenue & Share Analysis,
By Country
13.4.1 GCC
13.4.2 South Africa
13.4.3 Rest of MEA
13.5 Key Takeaways
14 SOUTH
AMERICA MARKET ANALYSIS
14.1 SA Market Revenue & Share Analysis,
By Route of Administration
14.2 SA Market Revenue & Share Analysis,
By Distribution Channel
14.3 SA Market Revenue & Share Analysis,
By Drug Class
14.4 SA Market Revenue & Share Analysis,
By Country
14.4.1 Brazil
14.4.2 Argentina
14.4.3 Rest of SA
14.5 Key Takeaways
15 COMPETITIVE
SCENARIO
15.1 Overview
15.2 Key Players Market Share Analysis
15.3 Recent Developments & Product
Launches
15.4 Mergers & Acquisitions
15.5 Partnerships, Agreements &
Collaborations
16 COMPANY
PROFILES
16.1 Overview
16.2 Key players
16.2.1 AstraZeneca
16.2.1.1 Business Overview
16.2.1.2 Products Offered
16.2.1.3 Financial Insights
16.2.1.4 Strategic Developments
16.2.1.4.1 New Product Launches
16.2.1.4.2 Agreements & Collaborations
16.2.1.5 Business Aspects (NOISE Analysis)
16.2.1.5.1 Key Strengths
16.2.1.5.2 Opportunities
16.2.1.5.3 Weaknesses & Competitive Threats
16.2.1.5.4 Needs & Improvements
16.2.2 AbbVie Inc.
16.2.3 Akebia Therapeutics, Inc.
16.2.4 Amgen Inc.
16.2.5 F. Hoffmann-La Roche
16.2.6 FibroGen Inc.
16.2.7 Johnson & Johnson Inc.
16.2.8 Pfizer Inc.
16.2.9 Teva Pharmaceutical Industries Limited
16.2.10 Reata Pharmaceuticals, Inc.
17 DISCLAIMER
18 APPENDIX
